Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low on Wednesday . The stock traded as low as $28.38 and last traded at $28.47, with a volume of 214570 shares changing hands. The stock had previously closed at $28.82.

Analyst Ratings Changes

COLL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. Finally, Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Trading Down 1.6 %

The stock has a 50 day simple moving average of $30.91 and a 200-day simple moving average of $33.58. The firm has a market capitalization of $914.29 million, a P/E ratio of 12.22 and a beta of 0.82. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently modified their holdings of COLL. New Age Alpha Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth $40,000. TD Private Client Wealth LLC increased its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in Collegium Pharmaceutical in the third quarter valued at $72,000. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.